PURPOSE: Participation in therapeutic clinical trials rarely reflects the race and ethnic composition of the patient population. To meet National Institutes of Health-mandated goals, strategies to increase participation are required. We present a framework for institutional enhancement of minority clinical trial accrual. METHODS: We implemented structural changes on four levels to induce and sustain minority accrual to clinical trials: (1) leadership support; (2) center-wide policy change; (3) infrastructural process control, data analysis, and reporting; and (4) follow-up with clinical investigators. A Protocol Review and Monitoring Committee reviews studies and monitors accrual, and the Program for the Elimination Cancer Disparities leads efforts for proportional accrual, supporting the system through data tracking, Web tools, and feedback to investigators. RESULTS: Following implementation in 2005, minority accrual to therapeutic trials increased from 12.0 % in 2005 to 14.0 % in 2010. The "rolling average" minority cancer incidence at the institution during this timeframe was 17.5 %. In addition to therapeutic trial accrual rates, we note significant increase in the number of minorities participating in all trials (therapeutic and nontherapeutic) from 2005 to 2010 (346-552, 60 % increase, p < 0.05) compared to a 52 % increase for Caucasians. CONCLUSIONS: Implementing a system to aid investigators in planning and establishing targets for accrual, while requiring this component as a part of annual protocol review and monitoring of accrual, offers a successful strategy that can be replicated in other cancer centers, an approach that may extend to other clinical and translational research centers.
PURPOSE: Participation in therapeutic clinical trials rarely reflects the race and ethnic composition of the patient population. To meet National Institutes of Health-mandated goals, strategies to increase participation are required. We present a framework for institutional enhancement of minority clinical trial accrual. METHODS: We implemented structural changes on four levels to induce and sustain minority accrual to clinical trials: (1) leadership support; (2) center-wide policy change; (3) infrastructural process control, data analysis, and reporting; and (4) follow-up with clinical investigators. A Protocol Review and Monitoring Committee reviews studies and monitors accrual, and the Program for the Elimination Cancer Disparities leads efforts for proportional accrual, supporting the system through data tracking, Web tools, and feedback to investigators. RESULTS: Following implementation in 2005, minority accrual to therapeutic trials increased from 12.0 % in 2005 to 14.0 % in 2010. The "rolling average" minority cancer incidence at the institution during this timeframe was 17.5 %. In addition to therapeutic trial accrual rates, we note significant increase in the number of minorities participating in all trials (therapeutic and nontherapeutic) from 2005 to 2010 (346-552, 60 % increase, p < 0.05) compared to a 52 % increase for Caucasians. CONCLUSIONS: Implementing a system to aid investigators in planning and establishing targets for accrual, while requiring this component as a part of annual protocol review and monitoring of accrual, offers a successful strategy that can be replicated in other cancer centers, an approach that may extend to other clinical and translational research centers.
Authors: Anjali S Advani; Benjamin Atkeson; Carrie L Brown; Bercedis L Peterson; Laura Fish; Jeffrey L Johnson; Jon P Gockerman; Marc Gautier Journal: Cancer Date: 2003-03-15 Impact factor: 6.860
Authors: Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: John H Stewart; Alain G Bertoni; Jennifer L Staten; Edward A Levine; Cary P Gross Journal: Ann Surg Oncol Date: 2007-08-08 Impact factor: 5.344
Authors: Soumya J Niranjan; Raegan W Durant; Jennifer A Wenzel; Elise D Cook; Mona N Fouad; Selwyn M Vickers; Badrinath R Konety; Sarah B Rutland; Zachary R Simoni; Michelle Y Martin Journal: J Cancer Educ Date: 2019-02 Impact factor: 2.037
Authors: Emily M Rencsok; Latifa A Bazzi; Rana R McKay; Franklin W Huang; Adam Friedant; Jake Vinson; Samuel Peisch; Jelani C Zarif; Stacey Simmons; Kelly Hawthorne; Paul Villanti; Philip W Kantoff; Elisabeth Heath; Daniel J George; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-05 Impact factor: 4.254
Authors: Carmen Radecki Breitkopf; Karen Patricia Williams; Jennifer L Ridgeway; Monica W Parker; Alice Strong-Simmons; Sharonne N Hayes; Michele Y Halyard Journal: J Womens Health (Larchmt) Date: 2018-07-05 Impact factor: 2.681
Authors: Ana Paula Cupertino; Mercedes Saint-Elin; Johana Bravo de Los Rios; Kimberly K Engelman; K Allen Greiner; Edward F Ellerbeck; Anna M Nápoles Journal: Oncol Nurs Forum Date: 2015-01 Impact factor: 2.172
Authors: Adebowale Odulana; Mimi M Kim; Melissa Green; Yhenneko Taylor; Daniel L Howard; Paul Godley; Giselle Corbie-Smith Journal: J Relig Health Date: 2014-04
Authors: Kathryn L Braun; Susan Stewart; Claudia Baquet; Lisa Berry-Bobovski; Daniel Blumenthal; Heather M Brandt; Dedra S Buchwald; Janis E Campbell; Kathryn Coe; Leslie C Cooper; Paula Espinoza; Ronda Henry-Tillman; Margaret Hargreaves; Aimee James; Judith Salmon Kaur; K Viswanath; Grace X Ma; Jeanne Mandelblatt; Cathy Meade; Amelie Ramirez; Isabel Scarinci; Sora Park Tanjasiri; Beti Thompson; Anissa I Vines; Mark Dignan Journal: Prog Community Health Partnersh Date: 2015
Authors: Betina Yanez; Heather L McGinty; David C Mohr; Mark J Begale; Jason R Dahn; Sarah C Flury; Kent T Perry; Frank J Penedo Journal: Cancer Date: 2015-09-08 Impact factor: 6.860